Company / R&D per Share
TEVA PHARMACEUTICAL INDUSTRIES LTD R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.91
FY2025
5-year range
$0.09 / $0.91
FY2021-FY2025
Trend
+0.7%
vs FY2024
Sector context
#150 of 208
Health Care
What the data says
At $0.91, TEVA PHARMACEUTICAL INDUSTRIES LTD's r&d per share ranks #150 of 208 in the Health Care sector. R&D per Share has increased for 3 consecutive years, from $0.09 in FY2022 to $0.91 in FY2025.
Based on SEC 10-K filings.
0.91 in FY2025 with a 5-year CAGR of -1.5%.
Improved from $0.86 to $0.91 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +116.3%
- 5-Year CAGR
- -1.5%
- 10-Year CAGR
- -
Sector benchmark
#150 of 208 in Health CareTop 72% of 208This company $0.91 Sector average $12.19
▼
-92.6% below sector average
Key checks
Key Insights
- TEVA PHARMACEUTICAL INDUSTRIES LTD's r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 0.7% year-over-year.
- Ranks #150 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.91 | +0.7% |
| FY2024 | $0.90 | +4.4% |
| FY2023 | $0.86 | +861.9% |
| FY2022 | $0.09 | -89.9% |
| FY2021 | $0.89 | -9.2% |
| FY2020 | $0.98 | -1.8% |
| FY2019 | $0.99 | -100.0% |
| FY2018 | $118626.43 | +68871016.4% |
| FY2017 | $0.17 | -100.0% |
| FY2016 | $439125.91 | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026